A randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis
- 1 October 2020
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (7), 783-792
- https://doi.org/10.1111/pai.13269
Abstract
Background Probiotic therapies, mainly live bacteria, have been proven to be effective in treating atopic dermatitis (AD) with some controversies. Killed probiotics or postbiotics would have immunomodulatory effect in allergic diseases including AD. This study was performed to evaluate the therapeutic effect and safety of tyndallized Lactobacillus rhamnosus (IDCC 3201, isolated from the feces of a Korean breastfed infant, repeated heat-treated and incubated, RHT3201) in children with AD. Methods In a randomized, double-blind, placebo-controlled study, RHT3201 at a dose of 1.0 x 10(10) CPU/d or placebo was given in children (aged 1-12 years) with moderate AD for 12 weeks. SCORing of AD (SCORAD) scores, allergic inflammatory markers, and safety parameters were evaluated. Results For evaluating the therapeutic effects of RHT3201, 33 subjects in each group were analyzed. The change of SCORAD total score at 12 weeks (primary outcome) from baseline was significantly greater in the RHT3201 group (-13.89 +/- 10.05) compared to the control group (-8.37 +/- 9.95). Levels of eosinophil cationic protein (ECP) and interleukin (IL)-31 showed tendency to decrease in the RHT3201 group and significant decreases in subgroup analysis in AD for >= 50 months. For safety analysis, a total of 100 subjects (50 in the treated group and 50 in the control group) were evaluated, and there were no significant differences in safety parameters between two groups. Conclusion In children with moderate AD, oral administration of RHT3201 showed the therapeutic effect on AD, the effects in part correlated with decrement of ECP and IL-31, and the effect was more remarkable in subgroup analysis.This publication has 28 references indexed in Scilit:
- Children with atopic dermatitis show clinical improvement after Lactobacillus exposureClinical & Experimental Allergy, 2015
- The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probioticNature Reviews Gastroenterology & Hepatology, 2014
- Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled TrialAllergy, Asthma & Immunology Research, 2014
- A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitisPediatric Allergy and Immunology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IJournal of the European Academy of Dermatology and Venereology, 2012
- Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow‐up until age 3 yearsClinical & Experimental Allergy, 2011
- Beneficial effect of a diet containing heat-killed Lactobacillus paracasei K71 on adult type atopic dermatitisThe Journal of Dermatology, 2010
- Effect of Lactobacillus sakei supplementation in children with atopic eczema–dermatitis syndromeAnnals of Allergy, Asthma & Immunology, 2010
- The probiotic paradox: live and dead cells are biological response modifiersNutrition Research Reviews, 2010
- Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in miceNature Immunology, 2004